What happened with NMRA today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Neumora Therapeutics is a clinical-stage drug developer focused on neuropsychiatric and neurodegenerative diseases. It builds its pipeline through internal research, acquisitions and licenses; candidates include navacaprant, NMRA-511 and its M4 programs. Most candidates remain in relatively early development.
Investors and lenders currently supply capital for development, rather than customers paying for marketed medicines. Future product sales depend on completing clinical trials and obtaining regulatory approval: Neumora cannot market its candidates before approval. It has no sales or distribution infrastructure and plans either to build those capabilities or outsource commercialization if a drug is approved. Government and private health insurers’ coverage and reimbursement would also affect its ability to sell medicines.
Neumora relies on outside manufacturers for all research and trial supplies, with single-source suppliers for key navacaprant and NMRA-511 supplies. It also depends on licensed intellectual property; those agreements require development efforts and milestone and royalty payments, and breaches can lead to loss of the rights.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Xenon Pharmaceuticals and Neumora are developing medicines for the same major depressive disorder and bipolar depression patients. Watch azetukalner’s Phase 3 depression results for how a competing treatment performs; Xenon has no product-sales revenue yet.
Alto Neuroscience challenges Neumora’s approach of using patient data to identify who is likely to benefit from neuropsychiatric medicines. Its clinical results in patients selected using measures such as EEG and genetic data are the comparison to watch for Neumora’s Precision Toolbox.
Axsome Therapeutics already sells AUVELITY in the U.S. for major depressive disorder, a market Neumora is pursuing, and both develop treatments for Alzheimer’s agitation. AUVELITY sales and Axsome’s agitation-program results are more relevant to Neumora than Axsome’s combined revenue from its three marketed drugs.
MapLight Therapeutics’ ML-007C-MA and Neumora’s M4 programs pursue competing schizophrenia treatments through muscarinic receptors. Watch the Phase 2 ZEPHYR results for ML-007C-MA, which combines an M1/M4 receptor activator with a drug acting outside the brain; MapLight has no revenue yet.
Neurocrine Biosciences competes with Neumora in depression medicines and schizophrenia treatments acting on muscarinic receptors. For this overlap, watch its direclidine, NBI-'570 and NBI-'567 programs rather than sales of INGREZZA and CRENESSITY through U.S. specialty pharmacies and distributors.
Bristol Myers Squibb already markets Cobenfy, a schizophrenia drug acting on muscarinic receptors that competes with Neumora’s M4 approach, and both develop Alzheimer’s agitation treatments. Watch Cobenfy’s commercial performance and Bristol Myers Squibb’s agitation-program results for these two areas of overlap.
AbbVie is developing depression medicines and emraclidine, a schizophrenia candidate acting on muscarinic receptors, in markets Neumora also pursues. Emraclidine’s clinical results are the specific comparison to watch for Neumora’s M4 programs, rather than AbbVie’s company-wide medicine sales.
Definium Therapeutics’ DT120 ODT, a lysergide treatment in Phase 3 development for major depressive disorder in 2025, competes for patients targeted by Neumora’s pipeline. Watch its depression results, but U.S. prescribing would also require a change in controlled-substance classification after FDA approval.
Helus Pharma competes with Neumora’s depression candidates by developing drugs designed to selectively activate serotonin receptors. Watch clinical progress across HLP003, HLP004 and HLP005; these are development programs, not marketed products generating sales.
COMPASS Pathways’ investigational COMP360 psilocybin treatment targets treatment-resistant depression, competing for depression patients also addressed by Neumora’s pipeline. Watch its results in that harder-to-treat group; if approved, COMPASS plans to market it to U.S. healthcare providers and clinic networks.
GH Research develops depression therapies that would compete with Neumora for patients needing new antidepressant treatments. Watch progress toward approval of GH001 and GH002; if approved, GH Research plans to reach healthcare providers, clinic networks and third-party payors in the U.S. and major European markets.
LB Pharmaceuticals’ oral candidate LB-102 overlaps Neumora’s pipeline in schizophrenia, bipolar depression and add-on treatment for major depressive disorder. Watch its Phase 3 schizophrenia program and planned Phase 2 add-on depression trial; LB has not commercialized a product yet.
Johnson & Johnson competes with Neumora through depression therapies under development or commercialization, and both pursue Alzheimer’s agitation treatments. Watch its depression and agitation programs specifically, rather than its broader prescription-medicine sales to wholesalers, hospitals and other healthcare channels.
Fed Interest Rate Decision
Neumora’s Fed-linked borrowing costs can rise or fall as the decision influences prime, the benchmark used in its K2 loan rate of the greater of 10.45% or prime plus 2.95%.
Expected4.0%Last release4.0%
If it comes in above expectations
If the decision is more rate-increasing than expected, prime may rise; once prime plus 2.95% exceeds the 10.45% floor, Neumora would pay more interest on its K2 loan, leaving less cash for neuroscience research and development.
If it comes in below expectations
If the decision is less rate-increasing than expected, or more rate-cutting, prime may be lower; if prime plus 2.95% is above the 10.45% floor, lower prime could reduce interest on Neumora’s K2 loan and leave more cash for research and development.
Bristol-Myers Squibb Co. earningsBMY
Bristol Myers Squibb's report will show whether patients and prescribers are taking up Cobenfy, a marketed muscarinic drug for schizophrenia, and update its work on Alzheimer's agitation, two areas that overlap with Neumora's pipeline.
Read Cobenfy's commercial performance alongside the update on Bristol Myers Squibb's Alzheimer's agitation program. Stronger Cobenfy performance would show that patients and prescribers are using a muscarinic schizophrenia drug, but would not establish that Neumora's candidates work; progress in the agitation program would add competition in another overlapping area. Weak signals on both fronts would offer less evidence of established demand or growing competition.
Axsome Therapeutics, Inc earningsAXSM
Axsome's report will show sales of its depression drug AUVELITY, a read on commercial demand among the major-depression patients Neumora also hopes to treat.
Watch whether AUVELITY sales grow. Stronger sales would show more commercial demand for a drug in the major-depression market Neumora targets, and make the value of competing for those patients and prescriptions clearer; weaker sales would be a softer demand signal, but would not determine whether Neumora's candidates will succeed.
Xenon Pharmaceuticals Inc earningsXENE
If Xenon Pharmaceuticals updates its Phase 3 azetukalner results, its report will show how another candidate is progressing in depression patients Neumora also targets.
Watch the results and progress of azetukalner's Phase 3 depression trial. Strong results would make it more plausible that this candidate could compete with Neumora for patients with major depression and bipolar depression; weak results would reduce the evidence that it is becoming a competitor, but would not show that Neumora's drugs work. The question is whether this rival pipeline is moving closer to a real treatment option.
Neumora Therapeutics, Inc. earningsThis company
Neumora has no product-sale revenue, so its report will show whether cash use and research spending leave room to keep developing its neuroscience candidates.
Read cash used in operations, ending cash and research and development spending together. A manageable cash draw with continued research spending would leave room for clinical development; faster cash use or a marked pullback in spending would mean less capacity to advance programs. The conclusion is whether Neumora's cash can continue to support its pipeline.
Alto Neuroscience Inc. earningsANRO
If Alto Neuroscience updates clinical results in patients selected using EEG or genetic data, its report will test a data-led way of matching patients to neuropsychiatric medicines against Neumora's Precision Toolbox.
Look at clinical results in patients selected using measures such as EEG and genetic data. Stronger results would suggest that this kind of selection may help identify people more likely to benefit, raising the bar for comparison with Neumora's precision-neuroscience approach; unclear results would leave Alto's added value harder to establish, but would not validate Neumora's toolbox. The conclusion is whether patient selection shows clinical value.
MapLight Therapeutics, Inc. earningsMPLT
If MapLight Therapeutics updates its Phase 2 schizophrenia results for ML-007C-MA, its report will show how a treatment sharing Neumora's M4-receptor focus is progressing.
Watch the Phase 2 results for ML-007C-MA. If this combination treatment, which activates M1 and M4 receptors, shows positive results in people with schizophrenia, it would add clinical evidence for a path close to Neumora's M4 programs and strengthen potential competition; weaker results would reduce that evidence, but would not settle the outcome of Neumora's programs. The conclusion is whether a treatment using a similar mechanism shows clinical promise.
